Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme

Neuro-Oncology

Volumn 13, Issue 4, 2011, Pages 393-400

  Fadul, Camilo E ^a   Fisher, Jan L ^a   Gui, Jiang ^b   Hampton, Thomas H ^b   Côté, Anik L ^a   Ernstoff, Marc S ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

Author keywords

Glioblastoma; Immune modulation; Radiation; Regulatory T cells; Temozolomide

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD40 ANTIGEN; CD56 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; DEXAMETHASONE; HLA DR ANTIGEN; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL MATURATION; CLINICAL ARTICLE; CLINICAL TRIAL; DENDRITIC CELL; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD CELLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY DOSAGE; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 79955767478     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq204     Document Type: Article

References (30)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
3. Rolle CE, Sengupta S, Lesniak MS. Challenges in clinical design of immunotherapy trials for malignant glioma. Neurosurg Clin N Am. 2010;21(1):201-214.
4. Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol. 2006;10(A):133-146. (Pubitemid 351976185)
5. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515-5525. (Pubitemid 41060828)
6. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res. 2004;10(16):5316-5326. (Pubitemid 39100466)
7. Liu G, Akasaki Y, Khong HT, et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma for chemotherapy. AACR Meeting Abstracts. 2005 2005;2005(1):1003a
8. Wang HY, Wang RF. Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy. Microbes Infect. 2005;7(7-8):1056-1062. (Pubitemid 40982675)
9. Crane CA, Han SJ, Barry 11, Ahn BJ, Lanier LL, Parsa AT. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol. 2010;12(1): 7-13
10. Gattinoni L, Klebanoff CA, Restifo NP. Pharmacologic induction of CD8+ T cell memory: better living through chemistry. Sci Transl Med. 2009;1(11):11ps12.
11. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004;22(4):610-616. (Pubitemid 41095063)
12. Hughes MA, Parisi M, Grossman S, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys. 2005;62(5): 1423-1426 (Pubitemid 40982064)
13. Briegert M, Enk AH, Kama B. Change in expression of MGMT during maturation of human monocytes into dendritic cells. DNA Repair (Amst). 2007;6(9):1255-1263. (Pubitemid 47238680)
14. Yagi H, Nomura T, Nakamura K, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells Int Immunol. 2004;16(11):1643-1656.
15. Roncador G, Brown PJ, Maestre L, et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol. 2005;35(6):1681-1691 (Pubitemid 40862316)
16. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev. 2006;212:203-216. (Pubitemid 44116710)
17. Learn CA, Fecci PE, Schmittling RJ, et al. Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res. 2006;12(24):7306-7315. (Pubitemid 46095402)
18. Ernstoff MS, Crocenzi TS, Seigne JD, et al. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res. 2007;13(2 Pt 2):733s-740s.
19. Sampson JH, Aldape KD, Gilbert MR, et al. Temozolomide as a vaccine adjuvant in GBM. J Clin Oncol (Meeting Abstracts). 2007 2007;25(18 suppl):2020
20. Chiba Y, Hashimoto N, Tsuboi A, et al. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. Jpn J Clin Oncol. 2010;40(5):395-403.
21. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31) 4722-4729.
22. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008;57(1):123-131 (Pubitemid 350043644)
23. Sun W, Jordan JT, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma secreted chemokines can be blocked with chemotherapy (Abstract) Neuro-oncol. 2007 2007;9(4):505.
24. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas Clin Cancer Res. 2008;14(16):5166-5172.
25. Briegert M, Kaina B. Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. Cancer Res. 2007;67(1):26-31 (Pubitemid 46142756)
26. Ardon H, Van Gool S, Lopes IS, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol. 2010;99(2):261-272
27. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14(10):3098-3104.
28. Atanackovic D, Panse J, Schafhausen P, et al. Peripheral T cells of patients with B cell non-Hodgkin's lymphoma show a shift in their memory status. Leuk Res. 2005;29(9):1019-1027. (Pubitemid 40982596)
29. Wu JY, Ernstoff MS, Hill JM, Cole B, Meehan KR. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Cytotherapy. 2006;8(2):141-148. (Pubitemid 43675200)
30. Rodrigues JC, Gonzalez GC, Zhang L, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol. 2010;12(4):351-365.